HKG:1177 Sino Biopharm

1 min read

HKG:1177 Sino Biopharm operates in the field of Medicine. The Group’s business works in a fully integrated chain which spans from R&D to manufacture and sales of pharmaceutical products, covering a vast array of biopharmaceutical, chemical and modernized Chinese medicines. Interim result 2022 are favorable for dividends (+200%) yet EPS fell 77%

HKG:1177 Sino Biopharm

Last update: 3-Aug-24

Quick overview:

    • Yield: 1.79%

(See here Top 10 highest yield)

    • Lot: 1000
    • Price/Earnings ratio : 23.33 (Ideal <20 )
    • Earnings per share : 0.120 (Ideal >0.001)
    • Price as per 3-Aug-24 : HK$2.80
    • Ex-Dividend Date coming up:  N/A

See here all upcoming Ex-Dividend dates

2024 Interim results: 0

Log in, to see this page

Get access to expert data in 5 minutes

Sign up now and get

  • The Blue Print Clarity on the 3 Pillars: Get a simple, step-by-step breakdown of the three key criteria that separate the long-term winners from the rest of the pack. No guessing—just a proven framework.
  • BONUS I The 25 highest yield dividend growth stocks .xls
  • BONUS II All 83 Hong Kong Blue Chips .xls

The Best Part? It’s completely free. No catch—just honest, data-driven insights that arm you with a consistent approach to dividend growth investing.

Build that portfolio

Selected or you: